Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.
Projectdetails
Introduction
Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, relies on a guide RNA (gRNA) – its program – to precisely cut a complementary genetic sequence – its target – for precision gene editing.
Applications of Programmable Nucleases
These programmable nucleases deliver cures for genetic diseases like:
- Anemia
- Blindness
- Cancer
They also facilitate quick disease model development and diagnostics for viruses like SARS-CoV-2.
Discovery of Nucleases
Hunts across microbial genomes have exposed thousands of programmable nucleases. Each could be another valuable tool for genome engineers, but we know just too little about them to use them safely.
Challenges with Off-Target Effects
Even Cas9 does not have guide-target parity: It cuts partially matched ‘off-target’ genome sites, which can lead to dangerous side effects. Though we work hard to avoid off-targets, partial matching may have a bright side.
Research Hypothesis
What if we leverage it, using it to make gene editing more predictable? Using high-throughput biochemistry, we will Profile nucleases and Repurpose Off-Targets to Expand Gene Editing.
The PROTÉGÉ Research Program
The PROTÉGÉ research program will:
- Profile guide-target parity – specificity – across promising, newly discovered programmable nucleases.
- Deliver a toolset for assessing this critical safety feature rapidly and broadly.
- Test the hypothesis that purposefully misprogramming nucleases can direct specific repair outcomes.
Conclusion
We intend to benefit Europe and the world community with safer and more diverse gene editing tools for achieving its Horizon Europe health, technology, and environmental goals.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.141.779 |
Totale projectbegroting | € 1.141.779 |
Tijdlijn
Startdatum | 1-6-2023 |
Einddatum | 31-5-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VILNIAUS UNIVERSITETASpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Harnessing a novel CRISPR nuclease for programmable counterselection in human cellsThis project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications. | ERC Proof of... | € 150.000 | 2024 | Details |
Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificitiesEditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases. | ERC Starting... | € 1.599.500 | 2025 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian CellsINTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations. | ERC Advanced... | € 2.475.491 | 2023 | Details |
Molecular mechanisms, functions and applications of RNA-guided DNA transposonsThis project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine. | ERC Starting... | € 1.499.403 | 2024 | Details |
Harnessing a novel CRISPR nuclease for programmable counterselection in human cells
This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.
Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificities
EditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells
INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.
Molecular mechanisms, functions and applications of RNA-guided DNA transposons
This project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
Next generation gene writing platform to cure genetic and oncological diseasesIntegra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases. | EIC Accelerator | € 2.496.375 | 2024 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
FluEdit: Microfluidics Gen-editing platform voor bloedcellenNTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie. | Mkb-innovati... | € 20.000 | 2023 | Details |
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
Next generation gene writing platform to cure genetic and oncological diseases
Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
FluEdit: Microfluidics Gen-editing platform voor bloedcellen
NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.